Literature DB >> 19409005

Cavernous carotid aneurysms: to treat or not to treat?

Christopher S Eddleman1, Michael C Hurley, Bernard R Bendok, H Hunt Batjer.   

Abstract

Most cavernous carotid aneurysms (CCAs) are considered benign lesions, most often asymptomatic, and to have a natural history with a low risk of life-threatening complications. However, several conditions may exist in which treatment of these aneurysms should be considered. Several options are currently available regarding the management of CCAs with resultant good outcomes, namely expectant management, luminal preservation strategies with or without addressing the aneurysm directly, and Hunterian strategies with or without revascularization procedures. In this article, we discuss the sometimes difficult decision regarding whether to treat CCAs. We consider the natural history of several types of CCAs, the clinical presentation, the current modalities of CCA management and their outcomes to aid in the management of this heterogeneous group of cerebral aneurysms.

Entities:  

Mesh:

Year:  2009        PMID: 19409005     DOI: 10.3171/2009.2.FOCUS0920

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  15 in total

1.  Giant cavernous carotid aneurysm with spontaneous ipsilateral ICA occlusion: Report of 2 cases and review of literature.

Authors:  Savitr Bv Sastri; Nishanth Sadasiva; Paritosh Pandey
Journal:  J Neurosci Rural Pract       Date:  2013-08

2.  Computed Tomography Angiography of Bilateral Intracavernous Internal Carotid Artery Aneurysms.

Authors:  Ayman G Elnahry; Gehad A Elnahry
Journal:  Neuroophthalmology       Date:  2018-03-26

Review 3.  Cavernous carotid aneurysms in the era of flow diversion: a need to revisit treatment paradigms.

Authors:  O Tanweer; E Raz; A Brunswick; D Zumofen; M Shapiro; H A Riina; M Fouladvand; T Becske; P K Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2014-08-21       Impact factor: 3.825

4.  Management of unruptured intracranial aneurysms: correlation of UIATS, ELAPSS, and PHASES with referral center practice.

Authors:  James Feghali; Abhishek Gami; Justin M Caplan; Rafael J Tamargo; Cameron G McDougall; Judy Huang
Journal:  Neurosurg Rev       Date:  2020-07-22       Impact factor: 3.042

5.  Pseudoaneurysm formation following intrasphenoid rupture of an idiopathic intracavernous carotid artery aneurysm: coil migration and early recurrence after endovascular treatment.

Authors:  R De Blasi; E Bracciolini; L Chiumarulo; A Salvati; C Monetti; F Federico; A Carella
Journal:  Interv Neuroradiol       Date:  2010-12-17       Impact factor: 1.610

6.  Improvement in Visual Symptomatology after Endovascular Treatment of Cavernous Carotid Aneurysms: A Multicenter Study.

Authors:  Doniel Drazin; Armen Choulakian; Miriam Nuño; Ravi Gandhi; Randall C Edgell; Michael J Alexander
Journal:  J Vasc Interv Neurol       Date:  2013-06

7.  Low-flow direct carotid-cavernous fistula caused by rupture of an intracavernous carotid aneurysm.

Authors:  I-Chang Su; Juan Pablo Cruz; Timo Krings
Journal:  Interv Neuroradiol       Date:  2014-08-28       Impact factor: 1.610

Review 8.  Orbital apex disorders: Imaging findings and management.

Authors:  Pradeep Goyal; Steven Lee; Nishant Gupta; Yogesh Kumar; Manisha Mangla; Kusum Hooda; Shuo Li; Rajiv Mangla
Journal:  Neuroradiol J       Date:  2018-02-08

9.  Intraoperative Computed Tomography (CT) for Treating Giant Carotid Intracavernous Aneurysms.

Authors:  Zhe Xue; Fuyu Wang; Zhenghui Sun; Hui Zhang; Chen Wu; Dongsheng Kong; Bainan Xu
Journal:  Med Sci Monit       Date:  2017-06-22

10.  Bilateral Cavernous Carotid Aneurysms: Atypical Presentation of a Rare Cause of Mass Effect. A Case Report and a Review of the Literature.

Authors:  Delia Gagliardi; Irene Faravelli; Luisa Villa; Guglielmo Pero; Claudia Cinnante; Roberta Brusa; Eleonora Mauri; Laura Tresoldi; Francesca Magri; Alessandra Govoni; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Front Neurol       Date:  2018-08-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.